Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Allink Biotherapeutics

Request full access

A clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics

ChinaFounded 2023Biotech & Life Sciences

About Shanghai Allink Biotherapeutics

Shanghai Allink Biotherapeutics, established in 2023 and based in Shanghai's Zhangjiang Hi-Tech Park, is a clinical-stage biotechnology firm focused on developing treatments for oncology and immunology. The company specializes in creating bispecific antibodies and antibody-drug conjugates (ADCs). Its business model centers on the research, development, and eventual commercialization of these novel therapeutics. Allink Biotherapeutics leverages its proprietary technology platforms to create next-generation treatments.

The company was founded by Dr. Hui Feng, who serves as CEO. Dr. Feng earned his Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine and has nearly two decades of experience in the biopharmaceutical industry. His background includes roles at Medimmune (an AstraZeneca subsidiary) and TopAlliance Biosciences. He notably led the development of Toripalimab, China's first PD-1 monoclonal antibody to receive overseas approval. The co-founders include Kehua Fan (COO), who has extensive experience in clinical development and external collaborations, and Dr. Li Li (Head of Research), who holds a Ph.D. from the Shanghai Institute of Materia Medica.

Allink Biotherapeutics' core focus is its pipeline of First-in-Class (FIC) and Best-in-Class (BIC) therapeutics. The company utilizes a proprietary bispecific antibody platform and a novel conjugation technology to produce bispecific ADCs (BsADCs). These are engineered for optimized drug-to-antibody ratios, improved hydrophilicity, and greater stability. The company's pipeline includes more than 10 candidates, with two lead assets, ALK201 and ALK202, having advanced to Phase I clinical trials in the United States, China, and Australia. These trials are assessing the safety, tolerability, and preliminary anti-tumor activity in patients with advanced solid tumors. In November 2024, the company secured $42 million in a Series A financing round led by Lanchi Ventures, with participation from investors such as Legend Capital, Yuanbio Venture Capital, and existing shareholders Gaorong Ventures and Med-Fine Capital. These funds are designated for advancing the clinical development of its lead candidates, enriching its pipeline, and expanding its global operations.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
58.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Dec 2025 $47M $188M Lapam Capital · 5Y Capital · Runzhang Venture Capital · Legend Capital ↗
SERIES AOther financing Nov 2024 $42M $168M Gaorong Capital · Yuansheng BioVenture · Xiamen C&D · Lanchi Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Allink Biotherapeutics website traffic

Latest recorded traffic for Shanghai Allink Biotherapeutics is 1.4K monthly website visits, up 197.9% over the last three months.

Latest monthly visits1.4K 3-month web change+197.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Allink Biotherapeutics in its local ecosystem

Live from Dealroom

The Shanghai Allink Biotherapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A10 investors entered at this stage

Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China60%
🇺🇸 United States40%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Allink Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Allink Biotherapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.